Search research articles
Contact Us
Filters
Showing results (11-20 of 79) with videos related to
Page
of 8
Sort By:
European Journal of Clinical Pharmacology
|
October 27, 2020
The PRECIS-2 tool seems not to be useful to discriminate the degree of pragmatism of medicine masked trials from that of open-label trials
Rafael Dal-Ré
Expert Review of Clinical Pharmacology
|
February 20, 2020
Participants' written informed consent in low-risk pragmatic clinical trials with medicines
Rafael Dal-Ré
Therapie
|
July 30, 2022
The winding 12-month journey of the AstraZeneca COVID-19 vaccine since its first administration to humans
Rafael Dal-Ré
Annals of Epidemiology
|
May 10, 2011
Worldwide clinical interventional studies on leading causes of death: a descriptive analysis
Rafael Dal-Ré
Revista Clinica Espanola
|
November 16, 2024
The rights and interests of participants as limits to clinical trials
Rafael Dal-Ré
Trends in Cancer
|
February 8, 2018
Clinical Trials Transparency: Where Are We Today?
Rafael Dal-Ré
Annals of the New York Academy of Sciences
|
August 5, 2025
Generalizability of glucagon-like peptide 1 receptor agonist clinical trial results to product labeling and the real world
Rafael Dal-Ré
Accountability in Research
|
October 30, 2020
For how long and with what relevance do genetics articles retracted due to research misconduct remain active in the scientific literature
Rafael Dal-Ré, Carmen Ayuso
Journal of Medical Genetics
|
July 14, 2019
Reasons for and time to retraction of genetics articles published between 1970 and 2018
Rafael Dal-Ré, Carmen Ayuso
Accountability in Research
|
January 24, 2024
The definition of research misconduct should be stated in the abstract when reporting research on research misconduct
Rafael Dal-Ré, Ana Marušić
Page
of 8
Search research articles
Search
Showing results (11-20 of 79) with videos related to
Sort By:
Page
of 8
European Journal of Clinical Pharmacology
|
October 27, 2020
The PRECIS-2 tool seems not to be useful to discriminate the degree of pragmatism of medicine masked trials from that of open-label trials
Rafael Dal-Ré
Expert Review of Clinical Pharmacology
|
February 20, 2020
Participants' written informed consent in low-risk pragmatic clinical trials with medicines
Rafael Dal-Ré
Therapie
|
July 30, 2022
The winding 12-month journey of the AstraZeneca COVID-19 vaccine since its first administration to humans
Rafael Dal-Ré
Annals of Epidemiology
|
May 10, 2011
Worldwide clinical interventional studies on leading causes of death: a descriptive analysis
Rafael Dal-Ré
Revista Clinica Espanola
|
November 16, 2024
The rights and interests of participants as limits to clinical trials
Rafael Dal-Ré
Trends in Cancer
|
February 8, 2018
Clinical Trials Transparency: Where Are We Today?
Rafael Dal-Ré
Annals of the New York Academy of Sciences
|
August 5, 2025
Generalizability of glucagon-like peptide 1 receptor agonist clinical trial results to product labeling and the real world
Rafael Dal-Ré
Accountability in Research
|
October 30, 2020
For how long and with what relevance do genetics articles retracted due to research misconduct remain active in the scientific literature
Rafael Dal-Ré, Carmen Ayuso
Journal of Medical Genetics
|
July 14, 2019
Reasons for and time to retraction of genetics articles published between 1970 and 2018
Rafael Dal-Ré, Carmen Ayuso
Accountability in Research
|
January 24, 2024
The definition of research misconduct should be stated in the abstract when reporting research on research misconduct
Rafael Dal-Ré, Ana Marušić
Page
of 8